Cuxavet TS Ogris
Cuxavet TS Ogris Uses, Dosage, Side Effects, Food Interaction and all others data.
Cuxavet TS Ogris inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.
Cuxavet TS Ogris is a semisynthetic antibiotic in the same class as penicillin. Cuxavet TS Ogris is for use against staphylococci that produce beta-lactamase.
Trade Name | Cuxavet TS Ogris |
Availability | Discontinued |
Generic | Cloxacillin |
Cloxacillin Other Names | Cloxacilina, Cloxacillin, Cloxacilline, Cloxacillinum |
Related Drugs | amoxicillin, doxycycline, ciprofloxacin, cephalexin, metronidazole, azithromycin, clindamycin, ceftriaxone, levofloxacin, Augmentin |
Type | |
Formula | C19H18ClN3O5S |
Weight | Average: 435.881 Monoisotopic: 435.065569098 |
Protein binding | Cloxacillin is approximately 94% protein-bound in plasma, primarily to albumin. |
Groups | Approved, Investigational, Vet approved |
Therapeutic Class | Penicillinase-resistant penicillins |
Manufacturer | |
Available Country | Austria |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Cuxavet TS Ogris is used for the treatment of infections caused by Grampositive organisms including infections caused by β-lactamase producing Staphylococci such as :
- Skin and soft tissue infections : Boils, Abscesses, Carbuncles, Furunculosis, Cellulitis, Infected wounds, Infected burns, Otitis media and externa, Protection of skin graft and Skin infections like ulcer, eczema, acne, etc.
- Respiratory tract infections : Pneumonia, Lung abscess, Empyema, Sinusitis, Pharyngitis and Tonsillitis.
- Other infections caused by sensitive organisms : Osteomyelitis, Enteritis, Endocarditis, Urinary tract infection, Meningitis and Septicaemia.
Cuxavet TS Ogris is also used to associated treatment for these conditions: Infection caused by staphylococci, Infections caused by penicillinase-producing staphylococci, Pneumococcal Infection, Streptococcal Infections
How Cuxavet TS Ogris works
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, cloxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cloxacillin interferes with an autolysin inhibitor.
Dosage
Cuxavet TS Ogris dosage
Upper Respiratory Tract Infection (Adult):
- Usual Dose: 250 mg orally every 6 hours for 7 to 14 days, depending on the nature and severity of the infection.
- Maximum dose: 4 g/day.
Upper Respiratory Tract Infection (Pediatric):
- Usual Dose: The safety and efficacy of cloxacillin in children < 1 year have not been established.
- ≥ 1 year to 18 years: 50 to 100 mg/kg/day orally divided every 6 hours.
- Maximum dose: 4 g/day.
Pneumonia(Adult):
- Usual Dose: 500 mg orally every 6 hours for up to 21 days, depending on the nature and severity of the infection.
- Maximum dose: 4 g/day.
Pneumonia(Pediatric):
- Usual Dose: The safety and efficacy of cloxacillin in children < 1 year have not been established.
- ≥ 1 year to 18 years: 50 to 100 mg/kg/day orally divided every 6 hours.
- Maximum dose: 4 g/day.
Skin and Structure Infection(Adult):
- Usual Dose: 500 mg orally every 6 hours for 7 days, or until 3 days after acute inflammation resolves, depending on the nature and severity of the infection.
- Maximum dose: 4 g/day.
Skin and Structure Infection (Pediatric):
- Usual Dose: The safety and efficacy of cloxacillin in children < 1 year have not been established.
- ≥ 1 year to 18 years: 50 to 100 mg/kg/day orally divided every 6 hours.
- Maximum dose: 4 g/day.
Cystitis:
- Usual Adult Dose: 250 mg orally every 6 hours for 3 to 7 days, depending on the nature and severity of the infection. Cuxavet TS Ogris is rarely indicated for the treatment of cystitis.
- Maximum dose: 4 g/day.
Side Effects
Common side effects are skin rash, transient diarrhoea, nausea, heartburn, pruritus and disturbance of blood electrolyte. Rarely anaphylactic shock.
Toxicity
Oral LD50 in rat and mouse is 5000 mg/kg. Intravenous LD50 in rat is 1660 mg/kg. Symptoms of overdose include wheezing, tightness in the chest, fever, itching, bad cough, blue skin color, fits, and swelling of face, lips, tongue, or throat.
Precaution
Cuxavet TS Ogris should be given with caution to patients with known history of allergy.
Interaction
May diminish the effect of BCG and typhoid vaccine. May increase risk of methotrexate toxicity. May diminish the therapeutic effect of Na picosulfate. May decrease serum concentrations of mycophenolate. May prolong bleeding time with anticoagulants. Increased serum concentrations with probenecid. Tetracycline may antagonise the bactericidal effect of cloxacillin.
Food Interaction
- Take on an empty stomach. Orally administered cloxacillin should be taken 1-2 hours prior to meals as the presence of food in the stomach and intestine reduces drug absorption.
[Moderate] ADJUST DOSING INTERVAL: Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.
The therapeutic effect of the antimicrobial may be reduced.
MANAGEMENT: The interacting penicillin should be administered one hour before or two hours after meals.
Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.
Cuxavet TS Ogris Hypertension interaction
[Moderate] Each 250 mg capsule of cloxacillin sodium contains approximately 14 mg (0.6 mEq) of sodium, and each teaspoonful of the 125 mg<5 mL oral solution contains approximately 11 mg (0.48 mEq) of sodium.
The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.
Cuxavet TS Ogris Drug Interaction
Unknown: aspirin, aspirin, epinephrine, epinephrine, amoxicillin / clavulanate, amoxicillin / clavulanate, ciprofloxacin, ciprofloxacin, acetaminophen, acetaminophen, multivitamin, multivitamin, thiamine, thiamine, cyanocobalamin, cyanocobalamin, pyridoxine, pyridoxine, cholecalciferol, cholecalciferol
Cuxavet TS Ogris Disease Interaction
Elimination Route
Well absorbed from the gastrointestinal tract.
Pregnancy & Breastfeeding use
Pregnancy Category B. Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Contraindication
Cuxavet TS Ogris should not be given to patients known to be hypersensitive to penicillin.
Storage Condition
Dry powder: Store below 25° C. Reconstituted solution: Store between 2-8° C (stable for 4 days); 23° C (stable for 24 hr).
Innovators Monograph
You find simplified version here Cuxavet TS Ogris
Cuxavet TS Ogris contains Cloxacillin see full prescribing information from innovator Cuxavet TS Ogris Monograph, Cuxavet TS Ogris MSDS, Cuxavet TS Ogris FDA label